High-potency active pharmaceutical ingredients (HPAPIs) place specific demands on your manufacturing operation. The regulatory landscape shaped by EMA, PIC/S, and FDA guidance has set increasingly specific requirements, tightening exposure limits and containment requirements that create new compliance obligations for drug developers and manufacturers.

Understanding what current HPAPI manufacturing compliance requires starts with how health-based exposure limits are derived and how OEB classification shapes facility design decisions. Those decisions carry downstream implications for process control documentation and the quality system requirements that regulators across multiple markets will scrutinize.

Compliance gaps in high-potency API manufacturing often go unnoticed until they surface in a regulatory submission or an audit finding. By that point, remediation is costly and time-consuming. This whitepaper from Pfizer CentreOne draws on deep HPAPI contract manufacturing experience to explain what a well-prepared program looks like in practice and what to address before issues arise.